Brawn Pharma shares closed at 21.35 on February 14, 2025 (BSE) and has given 18.61% returns over the last 6 months. Brawn Biotech Standalone Quarterly Results in Rs. Cr. Dec’24 Sep’24 Dec’23 Net Sales/Income from operations 3.84 3.30 2.84 Other Operating Income — — — Total Income From Operations 3.83 3.50 2.45 Increase/Decrease in Stocks -4.54 0.32 -0.28 Power & Fuel — — — Employees Cost 0.21 0.28 0.36 Depreciation 0.030.03 0.04 Excise Duty — — – Admin. And Selling Expenses — –. — Provisions And Contingencies — — — Exp. Capitalised — —- Other Expenses 0.58 0.56 0.51 P/L Before Other Inc. , Int., Excpt. Items & Tax – 0.43 -0,34 -0.,61 Other Income 0.000.00 0.01 0.02 P/ L After Tax from Ordinary Activities — — — Net Profit/(Loss) For the Period -0 (0.43) 0.34 0.61 EBITDA stands negative at Rs. 0.40 crore in December 2024 up 31.03% from Rs.0.58 crores in December 2023.
Brawn Pharma shares closed at 21.35 on February 14, 2025 (BS….
